4CPS-142 Analysis of prescribing and clinical outcomes of vedolizumab treatment in a university care hospital

BACKGROUND: Vedolizumab became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). The Spanish Drug Agency provided a Therapeutic Positioning Report about the clinical recommendation in the use of vedolizumab and its public funds. PURPOSE:...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur J Hosp Pharm
Главные авторы: Sanchez, E, Yañez, D, Carrion, IM, Montero, O, Martin, CB
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Group 2018
Предметы:
Section 4: Clinical pharmacy services
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535458/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.233
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы